Table 2.

WBMRI indices by group allocation.

WBMRI Indices	ADA, n = 25			Placebo, n = 24			Difference Between Groups in Change from Baseline, p^b
WBMRI Indices	Mean	SD	Change from baseline, p^a	Mean	SD	Change from baseline, p^a	Difference Between Groups in Change from Baseline, p^b
Peripheral joint
Synovitis index, range 0–92
Baseline	2.7	2.6		1.3	1.8
Wk 6	2.5	2.2	0.60	1.4	1.9	0.79	0.75
Wk 24	2.5	2.5	0.57	1.2	1.8	1.00	0.66
Wk 48	2.2	2.2	0.11	1.3	2.0	0.79	0.10
BME index, range 0–92
Baseline	0.9	1.3		0.4	0.7
Wk 6	0.8	1.3	0.59	0.5	0.7	0.35	0.18
Wk 24	0.6	0.9	0.12	0.3	0.6	0.23	0.70
Wk 48	0.6	0.8	0.11	0.4	0.6	0.77	0.36
Inflammation index, range 0–184
Baseline	3.6	2.9		1.7	2.1
Wk 6	3.3	2.7	0.57	1.9	2.3	0.43	0.50
Wk 24	3.1	2.6	0.23	1.5	2.0	0.89	0.41
Wk 48	2.8	2.3	0.10	1.7	2.1	0.65	0.12
Enthesis
BME index, range 0–30
Baseline	1.1	1.9		0.6	1.1
Wk 6	0.7	1.4	0.054	0.7	1.3	1.00	0.015
Wk 24	0.6	1.1	0.11	0.5	1.1	0.79	0.35
Wk 48	0.6	1.0	0.12	0.5	1.1	0.71	0.81
Soft tissue inflammation index, range 0–30
Baseline	1.4	1.7		0.6	0.8
Wk 6	0.9	1.6	0.15	1.0	1.3	0.29	0.064
Wk 24	0.8	1.5	0.038	0.8	1.1	0.60	0.032
Wk 48	0.8	1.5	0.073	0.8	1.3	0.57	0.054
Inflammation index, range 0–60
Baseline	2.5	2.9		1.3	1.5
Wk 6	1.6	2.3	0.040	1.7	2.2	0.24	0.032
Wk 24	1.4	2.0	0.027	1.3	1.9	0.92	0.12
Wk 48	1.4	1.8	0.048	1.3	2.1	0.90	0.22
Axial BME index, range 0–62
Baseline	2.5	3.8		3.0	3.2
Wk 6	1.0	2.0	0.003	2.8	3.1	0.50	0.049
Wk 24	1.0	2.1	0.008	0.9	1.9	0.002	0.45
Wk 48	1.4	2.4	0.051	0.9	2.5	0.002	0.34
Total BME index, range 0–184
Baseline	4.5	4.6		4.0	4.1
Wk 6	2.5	3.5	0.001	4.0	4.0	0.88	0.001
Wk 24	2.3	2.8	0.001	1.8	2.3	0.002	0.90
Wk 48	2.6	3.0	0.007	1.8	3.2	0.001	0.89
Total inflammation index, range 0–306
Baseline	8.6	6.3		5.9	5.7
Wk 6	6.0	5.1	0.005	6.3	6.4	0.48	0.004
Wk 24	5.6	4.6	0.001	3.7	4.5	0.002	0.64
Wk 48	5.6	4.3	0.009	3.9	5.6	0.004	0.58

Patients in the placebo group started ADA at Week 6. At Week 24, 6 patients stopped ADA and were switched to etanercept.
↵a Wilcoxon signed-rank test.
↵b Mann-Whitney U test. WBMRI: whole-body magnetic resonance imaging; BME: bone marrow edema; ADA: adalimumab.